Hypoxia VHL nad HIF in Renal Tumor Development

缺氧 VHL 和 HIF 在肾肿瘤发展中的作用

基本信息

  • 批准号:
    7216296
  • 负责人:
  • 金额:
    $ 24.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Clear cell carcinoma of the kidney (RCC), the most common form of kidney cancer, is associated with the inactivation of the von HippeI-Lindau (VHL) tumor suppressor. Mutations in the VHL gene can be found in approximately 70% of sporadic RCCs. One of the major functions of the VHL gene product, pVHL, is the targeting of the oxygen sensitive alpha-subunit of hypoxia-inducible factor (HIF) for ubiquitination and subsequent proteasomal degradation. Inactivation of VHL is felt to be an early event during RCC tumorigenesis and results in constitutive expression of two major HIF isoforms, HIF-1 and HIF-2. This results in increased transcription of genes that regulate glycolysis, angiogenesis and erythropoiesis. HIF-1 has furthermore been shown to up-regulate factors that promote growth arrest and apoptosis. The role of increased HIF expression in VHL associated tumorigenesis remains controversial. The hypothesis that the ratio of HIF-1 to HIF-2 levels is important for VHL associated renal tumor development will be investigated. Conditional gene targeting technology based on Cre-loxP mediated recombination as well as targeted transgenesis will be used to manipulate the expression levels of both pVHL and HIF in vivo and in vitro. This system enables the study of the functional relationship between VHL deficiency and HIF activation in regard to renal cell growth and viability in primary renal epithelial cells of different histogenetic origin. Specifically, the proposed investigations will examine the effects of increased or absent HIF-1 and increased HIF-2 expression in VHL deficient and wild type backgrounds. Studies will be performed in primary cell culture and in vivo with kidney specific conditional knock out mice. Gene expression studies will provide information regarding differential HIF-1 and HIF-2 target gene expression in different nephron segments with a special emphasis on genes involved in the regulation of cell survival. Taken all together, the proposed in vivo and in vitro studies will not only provide novel insights into the early events of renal oncogenesis and the histogenetic origin of RCC, but also examine fundamental aspects of HIF-1 and HIF-2 function in different nephron segments. Ultimately they have the potential to create a murine model of VHL associated renal tumors.
描述(申请人提供):肾透明细胞癌(RCC)是最常见的肾癌形式,与von HippeI-Lindau(VHL)肿瘤抑制因子的失活有关。大约70%的散发性肾细胞癌中可发现VHL基因突变。VHL基因产物pVHL的主要功能之一是靶向缺氧诱导因子(HIF)的氧敏感α亚基,以实现泛素化和随后的蛋白酶体降解。VHL的失活被认为是肾细胞癌发生过程中的早期事件,并导致两种主要的HIF亚型HIF-1和HIF-2的结构性表达。这导致调节糖酵解、血管生成和红细胞生成的基因转录增加。HIF-1进一步被证明可以上调促进生长停滞和细胞凋亡的因子。HIF表达增加在VHL相关肿瘤发生中的作用仍存在争议。假设HIF-1/HIF-2水平在VHL相关肾肿瘤的发生发展中起重要作用的假说将被研究。基于Cre-loxP介导的重组和靶向转基因的条件性基因打靶技术将被用于在体内和体外调控pVHL和HIF的表达水平。该系统能够研究VHL缺陷和HIF激活在不同组织起源的原代肾上皮细胞中对肾细胞生长和活力的功能关系。具体地说,拟议的研究将检验在VHL缺乏和野生型背景下HIF-1和HIF-2表达增加或缺失的影响。研究将在原代细胞培养和体内肾脏特异性条件性基因敲除小鼠中进行。基因表达研究将提供有关HIF-1和HIF-2靶基因在不同肾单位节段的差异表达的信息,重点是参与细胞生存调节的基因。综上所述,拟议的体内和体外研究不仅将为肾肿瘤发生的早期事件和肾癌的组织起源提供新的见解,还将研究不同肾单位节段中HIF-1和HIF-2功能的基本方面。最终,他们有可能建立与VHL相关的肾脏肿瘤的小鼠模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Volker Hans Haase其他文献

Volker Hans Haase的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Volker Hans Haase', 18)}}的其他基金

Mitochondrial electron transport dysfunction: Dissecting pathomechanisms
线粒体电子传递功能障碍:剖析病理机制
  • 批准号:
    10679988
  • 财政年份:
    2023
  • 资助金额:
    $ 24.65万
  • 项目类别:
Metabolic Reprogramming in Acute Kidney Injury
急性肾损伤中的代谢重编程
  • 批准号:
    8930970
  • 财政年份:
    2014
  • 资助金额:
    $ 24.65万
  • 项目类别:
Metabolic Reprogramming in Acute Kidney Injury
急性肾损伤中的代谢重编程
  • 批准号:
    9100699
  • 财政年份:
    2014
  • 资助金额:
    $ 24.65万
  • 项目类别:
Metabolic Reprogramming in Acute Kidney Injury
急性肾损伤中的代谢重编程
  • 批准号:
    8816559
  • 财政年份:
    2014
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    8966671
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    10587989
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    10427228
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    9275414
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    8633776
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:
Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
  • 批准号:
    10265319
  • 财政年份:
    2013
  • 资助金额:
    $ 24.65万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 24.65万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 24.65万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 24.65万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 24.65万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 24.65万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 24.65万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 24.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 24.65万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 24.65万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 24.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了